Replies to post #161707 on Biotech Values

[jq1234]

I take the contrarian view here. I think likely AZN seriously considered acquisition of AMRN. Uncertainty of NCE and valuation probably led to OMTH's Epanova. Epanova doesn't have much differentiation from Lovaza. I wonder whether Epanova could get mixed dyslipidemia indication Lovaza didn't. There is a market for prescription fish oil from big pharma, obviously at right valuation. Even though I had been negative on AMRN, I now see AMRN attractive down here.

[dav1234]

AstraZeneca's (AZN -1.5%) $443M deal to acquire Omthera puts the U.K. company at "distinct commercial advantage" over Amarin (AMRN +0.3%), says Decision Resources' Paramjit Narang. Omthera's Epanova drug "offers higher and more constant bioavailability, and arguably better efficacy" in lowering triglyceride than Amarin's Vascepa, and it "lacks the gastrointestinal side effects of the market incumbent Lovaza," which is sold by GSK (GSK -2%). Narang reckons Epanova's annual sales could peak at $1B